Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
August 6, 2026
Earnings Call Speaker Segments
Jennifer Good
executiveGood afternoon, and thanks for being here for our business update and earnings call for the second quarter of 2026. With me on today's call are my colleagues Dr. James Cassella, who serves as our Chief Development Officer; Farrell Simon, our Chief Commercial Officer; and David Hastings, our Chief Financial Officer. Dave and I will offer a few opening remarks, and after that the team would be glad to take whatever questions you have. For the company, 2026 is a significant year of execution, and the team is concentrated on delivering; this is an enjoyable aspect of what we do. Our plans for every program remain on track, and during the second quarter we launched both the OCEAN-1 Phase III 52-week trial in patients with IPF-related chronic cough and the LAKE Phase IIb trial in patients with refractory chronic cough, or RCC. Additionally, we intend to launch the second Phase III 12-week trial in patients with IPF-related chronic cough, called OCEAN-2, in the third quarter; so it has been a busy summer for team Trevi. The team is concentrated on activating global sites for all of these trials, which add up to more than 200 sites. I have been present at all of our investigator meetings so far, and there is an enormous amount of enthusiasm and energy regarding participation in our trial and the substantial unmet need in chronic cough. Enrollment for the 2 trials that have been launched is at an early stage, but our plans remain on track. As soon as we reach roughly 50% enrollment in any of our trials, we will reveal that milestone and afterward provide enrollment updates on our quarterly earnings call. So expect further details as we make progress. The third element of our story involves patients with non-IPF-ILD-related chronic cough. We just filed a meeting request with the FDA to talk about this program, and we expect to learn this month whether the meeting has been granted. If it is granted, we will file the full protocol and briefing document to discuss the next trial and the development plan for this indication. There are many synergies between this ILD patient population and our IPF studies, since these patients with non-IPF-ILD are seen at the same care centers by the same pulmonologists; so while we negotiate CDAs, contracts and budgets for our IPF-related chronic cough trials, we are keeping this trial within scope so that we can move quickly once we have FDA alignment. Looking ahead to the remainder of this year, here are the key milestones you should anticipate from us. First, we expect alignment on our chronic cough program that isn't tied to IPF-ILD during the latter half of this year. Second, we aim to reach 50% enrollment in the Phase IIb LAKE trial for RCC, also in the latter half of this year. Third, we anticipate results from the sample size reestimation, or SSRE, for the LAKE trial in RCC, which will be available once 50% of patients have completed the trial and an external unblinded statistician has performed the analysis. The SSRE was built into the protocol to verify powering assumptions and make sample size adjustments if needed. We expect the SSRE readout in Q4 of this year, which has drawn increased attention following the recent discontinuation of a competing RCC program. I'd also like to mention a significant medical conference that took place in Q2, the American Thoracic Society, or ATS, meeting. All 6 of our submissions were chosen for either presentations or posters, spanning a variety of data from our Phase II trials. This encompassed new findings on breathlessness reduction with nalbuphine ER in patients suffering from IPF-related chronic cough, decreases in cough bouts for both IPF chronic cough and RCC — something quite meaningful for patients — as well as an analysis demonstrating the impact of nalbuphine ER across all baseline cough counts, from fewer than 10 coughs per hour and above, which essentially showed nalbuphine ER's robust response in patients regardless of cough count. These presentations are available on our corporate website. Lastly, we were honored that Trevi's JAMA publication of the Phase IIb CORAL trial for treating patients with IPF-related chronic cough was highlighted at the ATS 2026 International Conference Clinical Year and Review session. Dr. Lida Hariri of Harvard Medical School featured the CORAL trial results among the year's key developments in ILD research. ATS was a significant meeting for Trevi and reflects the growing awareness of the burden chronic cough places on patients; during Q2, we also introduced our unbranded campaign to raise awareness of the disease burden of chronic cough among pulmonologists. This campaign features patient testimonials in IPF and non-IPF-ILD and their lived experiences with chronic cough. Through our digital efforts, we've reached over 17,000 unique pulmonologists thus far and witnessed overwhelming engagement, underscoring physicians' eagerness for new therapies for their patients. To wrap up, we are committed to executing our plan to become the leader in chronic cough; given the recent competitive failure in RCC, we are essentially alone in all 3 of our cough indications and have the opportunity to be a first-in-class therapy where significant unmet need exists. We recognize the great responsibility we have to deliver nalbuphine ER and potentially help patients across these indications. A great number of doctors, businesses, patient advocacy organizations, and individuals living with this condition have devoted their time and resources toward building up the chronic cough space, driven by a desire to make life better for those patients; we are embracing that duty and keeping our attention fixed on pushing Haduvio across the finish line. Our belief is that should we succeed in carrying out the plan we have right now, we can generate meaningful value for patients and, as a result, substantial value for our shareholders. At this point I will hand things over to Dave so he can share his comments, after which we will gladly take your questions. Dave?
Dave Hastings
executiveThanks, Jennifer, and good afternoon, everyone. Today I'll concentrate on the financial measure that matters most to us, our cash position and the runway it gives us. As of the close of the second quarter of 2026, we held roughly $319 million in cash, cash equivalents and marketable securities. The key point is that we remain on track with our budget and plans for this year thus far, with the team continuing to execute on our clinical trials. As a result, our cash runway guidance has stayed the same since our previous quarterly call, and it reaches into 2030. This runway guidance covers funding our development program in patients with IPF-related chronic cough all the way through potential FDA approval; beyond that, we expect these resources to allow the company to fund the clinical development program through Phase III for treating patients with non-IPF-ILD-related chronic cough, plus the ongoing Phase IIb LAKE trial for treating patients with RCC; the planned use of these resources also covers pre-commercial activities, though it excludes any expenses tied to a commercial launch of Haduvio or a Phase III clinical trial in RCC; so given all that, I believe we are well positioned to execute our clinical trials with sufficient funding through critical high-value inflection points. Operator, we can now open the call for questions.
Roanna Ruiz
analystR (Roanna Clarissa Ruiz): Alright, I have a few things to ask. I'm interested in that FDA session you have coming up regarding ILD chronic cough. What kind of questions do you think the agency will put to you? Also, might you share some detail on the possible approaches when it comes to designing a trial protocol for patients with ILD chronic cough, especially compared with what you've already set up for IPF chronic cough?
Jennifer Good
executiveS (Jennifer Good): Sure. Jim, over to you.
Jim Cassella
executiveRoanna, Jim here. Thanks for asking that. Essentially, what we'll have with the FDA is an alignment meeting; it's common knowledge that our IPF program is solid. What we're focused on now is broadening that into the non-IPF-ILD population. So much of what came up during the end of Phase II meeting regarding IPF patients is going to serve as the basis and the foundation when we speak with them about the non-IPF-ILD program. As you'd expect, the protocol will track very closely with what we're doing in the OCEAN program. Naturally, what differs is the character of the patient population. But as you can imagine, when it comes to endpoints and similar matters, everything will stay the same. So really, it comes down to alignment on the inclusion/exclusion criteria now that we're looking at the non-IPF population, and we'll examine other parameters for the protocol that are quite specific yet not very different relative to what we already did for IPF. So it truly is about alignment on that, and then on the pathway toward an NDA filing for that indication. So really, this will be a meeting where we hold that discussion, reach finality on our approach, and then execute against the plan we walk away with.
Roanna Ruiz
analystThat makes sense. I was also wondering about RCC — since a competitor of yours just ended their program, does that shift how you see the broader market landscape, or any views on pricing and so on? And as we head toward the SSRE for the LAKE trial, any fresh thinking there? And how are you considering whether it might need to be upsized or not?
Farrell Simon
executiveRoanna, it's Farrell here. I can take your question about how we're approaching RCC. We are a company led by IPF-ILD, and that really sets up the specialty commercial dynamics we plan to bring into the market. How we approach RCC has not changed. So we plan to go after the treatment-resistant share of those RCC cases, which is still a substantial share, roughly 1 million patients in the U.S; and a big market opportunity. And that lets us bring those specialty dynamics and specialty pricing into that indication. So with the recent competitive news, it has not changed.
Jim Cassella
executiveRegarding Roanna's question about the trial — that's the LAKE trial and the SSRE — what that study rests on comes out of our RIVER research, or rather, apologies, it comes from the results we generated in RCC along with what our CORAL program showed us. So the notion that an outcome from GSK could somehow sway us truly has no bearing whatsoever on our study; the powering of that study relies on our own data and on the assumptions we examine for a parallel arm study, which is where CORAL information enters the picture. From a clinical standpoint, then, as far as we're concerned, our program is propelled by data we generated ourselves; we're aware that we possess extremely potent, best-in-class style efficacy within the RCC patient population. The effect size we have is quite robust, and that is genuinely what propels that study; so what GSK's figures were, we don't know. What effect sizes they had, we don't know either, yet I believe it genuinely has 0 impact on our clinical program.
Jennifer Good
executiveHaving that provision in place gives our program some cover, which feels good, since none of us can really see clearly where placebo stands right now. So the benefit of including it, I'd say, is that it ought to shield the program as a whole should an effect exist.
Annabel Samimy
analystNice to see the momentum. I just want to get some clarity regarding the SSRE for the programs you're running — does that apply solely to LAKE, or does it cover the OCEAN programs too?
Jim Cassella
executiveThis is Jim. Right. No, LAKE is the only one. Essentially, it's the Phase II trial. OCEAN has strong power. We know our effect size from the CORAL study, and that program has no interim read.
Annabel Samimy
analystAll right, understood. Now regarding RCC, I'd like to dig a bit deeper into what's actually available there. My understanding is that at first the plan involved targeting those hardest-to-treat cases, people who in all likelihood had already gone through every available treatment, based on the idea that another approved option would exist on the market. What this appears to do, then, is essentially throw the doors open to the entire patient group for you. So could you walk us through how you might, say, break that group into smaller segments?
Farrell Simon
executiveFarrell here. That's a really good question. There's a degree of flexibility we have when it comes to RCC. What matters is getting a clear picture of the dose that emerges from our Phase II study. Should we land in the very low dose range — let's say 27 milligrams taken once daily or lower — then there's a real possibility of unlocking that market through a different route, using a second brand with differentiated pricing. On the other hand, if we stay — if the dose comes out comparable, one thing we're keen to avoid is eating into our IPF or ILD patient base and the revenue tied to it; in that case we'd remain with the strategy we have now. The direction here really comes from the discussions we've held with payers, along with thorough payer research we've conducted, to confirm we're reaching patients facing the greatest unmet need, ones who have already tried possibly even some of these off-label treatments without success.
Annabel Samimy
analystUnderstood. And if there truly aren't other therapies out there, which patient would be the most severe? Would cough count be the deciding factor?
Farrell Simon
executiveIn practice, though, cough counts aren't something we'd actually have, correct? The main basis would be a cough severity NRS score, which serves as a key secondary endpoint in our trials. Much of our IE criteria is what this will line up with; for instance, in our Phase II trial, RCC patients enrolled have lived with the condition for more than a year. That begins to split this population into segments. Another thing we can do well on is reaching patients who are under specialist care, primarily pulmonologists. So once you break down what this population actually consists of, it comes down to that 1 million target we've discussed, which we've labeled treatment resistant.
Jennifer Good
executiveRight. Annabel, I'd like to draw a line here, since that's where your question is pointing. From a clinical standpoint, a wide indication is what we'll end up with. We could target that entire patient group. On the commercial side, since IPF is our lead indication, holding things at the level of specialty prescribers works in our favor, because that lets us protect our pricing. So regarding what you're asking, I believe it's a positive, given that the low dose gives us optionality <<inaudible>>. That means we'll enjoy the greatest possible flexibility. Still, under the scenario we're currently preparing for, we will need to stay conscious of payer restrictions of one kind or another.
Annabel Samimy
analystUnderstood. Understood. Then, one final item. Until your Type C meeting, I doubt you're able to respond to this just yet. However, regarding the Phase IIb ILD trial, or the non-IPF-ILD trial, should the results be positive, is there a route toward a broad interstitial lung disease label? Alternatively, would another Phase III truly be required? Or what's your plan for incorporating that — have your thoughts shifted on how you'd work that into the IPF indication, since functionally and pathophysiologically they're the same?
Jim Cassella
executiveYes. Annabel, Jim here; so I believe our strategy for the non-IPF-ILD program is to devise the most efficient protocol that brings us to an NDA as fast as possible. Therefore, certain matters can be discussed with the FDA. Yet I think you may assume those programs will proceed in parallel, and we'll design and hopefully secure agreement on the most efficient route to the NDA. So that's clearly TBD depending on our talks with the FDA; but as you noted, we have a solid foundation here that this is all IPF, non-IPF. This is interstitial lung disease. It's the lung disease that every KOL believes is mediating the cough, and that's our common thread here; so we'll be very interested in discussing the most efficient pathway to get that population to approval.
Judah Frommer
analystWe realize it's still early days here, but do you have any perspective on what the potential spend might look like to build awareness in RCC once potential commercialization happens — something where maybe one could argue it would've been great to have a large pharma partner assist with that? Or is this market large enough that the possible absence of competition is really the main takeaway?
Farrell Simon
executiveJudah, Farrell here. Thanks for asking. We return to the fact that we remain a company led by IPF and ILD. And the nice thing about that setting is that within the United States there are 90 ILD care centers. So the approach is fairly focused. Like we've said, we're starting this off with pulmonologists serving as the primary call point. And truly, that will remain the call point until we reach the market with the RCC indication, which they'll be acquainted with since we'll already be calling on them for another indication. So indeed, they might have established the RCC awareness if they were going to market, and sadly, that won't be present, yet we have the means to genuinely become leaders in chronic cough and to shape our own narrative so that this stays top of mind. You brought up the spend required for that. Our approach is a highly efficient digital one, and the engagement we're seeing here is great. As launch gets closer, we'll ramp that up, but all of it falls under pre-commercial planning.
Leland Gershell
analystTracy here, filling in for Leland. Nice work on the quarter. Since the trial designs look quite alike for non-IPF-ILD cough and IPF chronic cough, we wanted to ask whether pulmonologists have given you any input on an efficacy threshold they'd want to see. Or is there anything important we ought to bear in mind regarding how efficacy gets characterized between these conditions or indications?
Jim Cassella
executiveJim speaking. The feedback from KOLs has been quite emphatic that when it comes to what causes the cough — with the lung disease being the real driver — IPF and non-IPF-ILD can essentially be treated as interchangeable. Given the IPF data we hold, the thinking is that efficacy will be very strong in both of those patient groups. So there's nothing unusual on that front. In a sense, from their perspective, it amounts to an obvious call. That said, the data will ultimately speak for itself, and we have to ensure we conduct the proper trial to genuinely tease this out. Still, nothing differs in what we ought to be watching for. Every endpoint will remain identical. So really there are no distinctions, apart from now characterizing it within the other portion of the ILD space.
Ryan Deschner
analystNice work on the momentum. During Investor Day, you emphasized how you're prioritizing efforts tied to growing your intellectual property footprint. Any further step-by-step news on that side? Then I've got another thing to ask.
Jennifer Good
executiveSure, that's a solid one, Ryan. As the two of us have talked about, quite a bit is happening in that area. We have many incremental patents getting submitted, though prosecution takes a while and they must move through the system. So nothing newly issued — and that's truly the thing we'd report once a quarter has passed — yet plenty has been happening. My recollection is that in only the most recent few months, we submitted 3 additional patent applications. So it's somewhat of a — you'll need to take my word for it situation, but a major push is underway there. And at some future moment, these will begin coming through and being granted.
Ryan Deschner
analystAll right. Since those end of Phase II meetings, or the Investor Day when you last discussed this, have there been any further interactions with the FDA that have changed, even slightly, how the studies you've already started this year are designed? And I'd also like to know how much turnover has occurred this year within the FDA division you've been dealing with?
Jim Cassella
executiveRyan, it's Jim here. There have been no fresh interactions concerning trial design or anything of that nature. Like Jen said, we've now launched both LAKE IIb and the Phase III OCEAN trial in IPF. So everything is on track there. We're in execution mode. Right. On the turnover question, I'd say the team looks like the same one we've dealt with previously. To our knowledge, nothing significant has shifted there. Leadership appears unchanged — the same group we spoke with at the end of Phase II meeting. Whether anything has changed lower down in the FDA ranks, I can't say, but those we're in contact with remain the same individuals as before.
Kaveri Pohlman
analystWayne here, filling in for Kaveri. Nice work on everything you've accomplished. To start, I'd like to dig deeper into the SSRE. Could you describe the possible paths that could come out of that analysis? More specifically, should a larger sample size be needed, what should investors expect regarding how big that adjustment would be and how it might affect when readout occurs? Also, aside from objective cough frequency, how do you view secondary endpoints' contribution within the OCEAN trials when it comes to backing up the overall efficacy picture and possible labeling? Which clinical benefit measures do you think matter most for shaping the product profile?
Jim Cassella
executiveJim speaking here. Regarding the SSRE, this closely mirrors our approach in the CORAL program. At the SSRE point, we aim for 80% conditional power. The unblinded statistician will let us know if an increase is necessary, since we lack 80% or higher conditional power when enrollment reaches the 50% mark. Should we fall below that threshold, clearly the sample size would grow accordingly, and a futility threshold also exists. As for having to enlarge the sample size, from my clinical viewpoint it isn't a major concern. In some respects, it's a mathematical workout examining the assumptions we brought in. This marks our initial parallel group design study involving RCC patients. We picked up certain lessons from our crossover study. There are also insights gained from the IPF program, and we incorporated those into this protocol. Through the SSRE, we'll put those assumptions to the test. Thus, the cutoff is 80% conditional power. If upsizing becomes necessary because we fall slightly short of that, that's a statistical matter. To my mind, it truly doesn't carry an impact. It indicates we can get there, and given our assumptions, perhaps with a bit more enrollment. So I don't attach any meaning to that. I believe we're able to go as high as a 50% increase for the protocol's sample size. So once more on this topic, I don't view anything as — I wouldn't interpret an increase, if we had to do one, as meaningful; it's a statistical matter, yet it shows we can hit 80% conditional power, which is the target, and we can achieve that through this rise in enrollment. That covers that aspect. Turning to the Prurigo side and the key secondary endpoints regarding the OCEAN program, these were thought through very carefully. We have several key secondary endpoints. Many of them rest on patient-reported outcome measures, with cost severity being the initial and most critical one. There's also the breathlessness endpoint included in our program. We're aware that these matters carry significant weight for both the people writing prescriptions and those receiving treatment. Therefore, the key secondary endpoints that were talked about with the FDA during the end of Phase II meeting are genuinely designed to strengthen what we learn regarding cough reduction from the patient's point of view, along with some additional examination of what's happening when it comes to lowering cough. So we do include the number of individuals who achieve a 50% reduction; there's genuinely useful information contained in that. Should we succeed on those key secondary endpoints within the hierarchy, they become label enabling. And since we talked about them and disclosed them as key secondaries in the hierarchy, there's a strong probability that we can secure them in the label, though naturally that hinges on discussion with the FDA.
John Gionco
analystJohn Gionco here, filling in for Serge at the moment. Nice work on everything you accomplished during this quarter. We've just got one question today. Turning back to the LAKE trial — obviously, you began enrolling participants during the prior quarter. Now that you're essentially the recognized frontrunner when it comes to RCC development, I'm wondering whether you're noticing any shifts in patterns around how quickly patients are signing up. I realize it's still early days, but any detail you can share would be appreciated.
Jennifer Good
executiveIt's really quite early. Let me take that one. Both Jim and I attended every single investigator meeting. And there's — what I mean is, no one else is competing for enrollment. The timing also works in our favor, since everyone just introduced these GSK trials — 2,000 patients in total. That gives us a solid list of who more or less met the criteria for those studies; so Jim, the two of us share a fairly optimistic view about our capacity to more or less move patients over into our studies.
Jim Cassella
executiveSo I'd say what really stood out from that investigator meeting in RCC was how much enthusiasm people showed, and that was true even ahead of all the news, the most recent news. Our drug is generating a great deal of excitement in RCC. And honestly, I believe that's the main force behind the enthusiasm we're seeing for enrollment.
William Wood
analystAlright, two from me if that's okay. OCEAN-2 is set to report in the back half of 2027, while OCEAN-1 comes in the front half of 2028 — so how long would you plan to keep the OCEAN-2 data under wraps before OCEAN-1 reports, essentially releasing both at once? And if, given the timing, you decide to keep them apart, how much could we infer from OCEAN-2 about OCEAN-1, considering the differing durations of 12 weeks against 24 weeks? I'm basically trying to figure out how much weight we should place on OCEAN-2 when looking at OCEAN-1, or the reverse. Then my second one: now that GSK has exited, what's shifted in your strategic talks — both the volume of them and the way those discussions get framed with your team?
Jennifer Good
executiveYes. William, this is Jennifer. No, we won't be holding the top line — we're a small outfit. That kind of luxury isn't available to us. It has to go out, since all of you will be pressing us at every conference, and I'm hopeless at poker. Jim typically hands it to me over the weekend once results are known, and we release them Monday morning, so out they go. We'll also be careful about how heavily we push that into the sites, because influencing the trial is not something we want. By then, though, our OCEAN-1 trial ought to be mostly enrolled, with participants quite far along, so only a modest proportion could be impacted. You raised the topic of strategics. This Glaxo news is fresh off the press, and I can't claim to have a firm read on it yet. Everyone recognizes the sizable opportunity in cough. Translating from Phase II into Phase III has clearly been difficult. One advantage for us, I believe, is that our effect size is considerably larger. And my view is that IPF hasn't suffered from those placebo effects — but on the strategic front, truly no comment. As for your question on whether 12 weeks translates to 24, that's a fair one. Everything in OCEAN-1 and 2 has been studied in CORAL, and the translation from that study was very solid, so the open question, I'd say, is how things move from 6 weeks in CORAL to 12 weeks in OCEAN-2 and then to 24 weeks in OCEAN-1. I've said previously that we tested this drug in prurigo nodularis over a year and saw no fading of effect, and Jim can wow you with the receptor pharmacology explaining why we wouldn't. Still, that's the question, I think. A good positive response at 12 weeks with nothing odd showing up — personally, Jim, you should weigh in, but I see it as a solid read-through to 24 weeks.
Jim Cassella
executiveAbsolutely, Jen — what matters most here, I believe, is that both of these studies have solid statistical power. Nothing gives us cause to expect that efficacy would diminish as dosing continues. Jen, I think, brought up the PN trials we conducted earlier. For pharmacological reasons that I won't get into, since it would put everyone to sleep, I have grounds for that view. So my take is that these are separate trials, each with a different length of study. Both should, in my view, mirror what we observed previously, and nothing in my thinking suggests we'd encounter any weakening or disappearance of the effect the further out you go.
William Wood
analystUnderstood. Perhaps one brief additional question. Regarding any further insights from CORAL that you might have brought into this, considering the shift from Phase IIa to Phase IIb, your overall effect size moved somewhat. Did you add anything else, or make other modifications, in OCEAN that could potentially enhance or maintain that same effect size?
Jim Cassella
executiveWhen it comes to IPF, the effect size we observed in the CORAL program was quite robust. Into the OCEAN program, we applied somewhat cautious powering derived from the effect size we observed there. Honestly, I don't anticipate any variations. I suppose we'll find out how things truly unfold as time goes on. Even so, we remain adequately powered. The effect size we had was very strong. So I'm not certain that truly addresses your question in the sense that, yes, apart from what we previously discussed, there's nothing new, but it rests on the solid effect size we possess, and we've powered things somewhat cautiously to safeguard that.
Conor MacKay
analystCongratulations on everything you've accomplished so far. I have just 2 brief follow-ups. Considering our understanding of how heterogeneous the RCC population is, I was curious whether you could describe the measures being taken to ensure the correct patients are being enrolled and that we'll observe the greatest benefit from Haduvio. Then, since there are several data readouts expected in 2027, could you discuss how far physician engagement has come and perhaps how your approach varies between the pulmonary fibrosis and refractory chronic cough initiatives?
Jim Cassella
executiveRegarding your question about patients, we — for RCC, a placebo run-in period has been added; that came about through insights from KOLs who have spent a long time working in the RCC space. The key is selecting sites with proper experience, ensuring the entry criteria are correct; we are — no formal adjudication happens, but each patient entering the trial gets assessed by our internal team alongside the site PIs. So we're being as rigorous as possible. In this population, I think it's truly important to confirm that every inclusion criterion is met; all of those are built in according to input from the KOLs and individuals who've had experience with these trials where some trip-ups have occurred.
Farrell Simon
executiveYes, Conor, Farrell here. Thanks for asking. Regarding how we're involving physicians as 2027 comes closer and that initial set of data readouts arrives, as we mentioned, we launched this unbranded effort during Q2, and its core purpose is elevating awareness around the burden of disease tied to IPF and ILD. Since IPF and ILD sit at the center of who we are, we're going to remain focused there for a good while. That said, as we noted, pulmonologists represent the main call point and the objective for everything we're doing in outreach, and those community puls do overlap with RCC, so our engagement does create some halo effect. We'll begin with the unbranded campaign delivered digitally. From there, we'll build it into a bigger presence at Congress, and we're working hand in hand with our medical affairs colleagues to ensure we hit the right targets.
Jennifer Good
executiveAlso, Farrell, I want to mention that you folks are working directly with patient advocacy organizations, and through those efforts you're reaching all the networks and physicians too.
Jennifer Good
executiveWe appreciate you being with us on today's call, and we hope the remainder of your summer is enjoyable. Should you have any additional questions, we're here to help. Thank you.
Operator
operatorThis does conclude today's conference call. Thank you for attending. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.